Abbott Laboratories (ABT) is a publicly traded Healthcare sector company. As of July 5, 2026, ABT trades at $95.40 with a market cap of $166.17B and a P/E ratio of 26.57. ABT moved +3.38% today. Year to date, ABT is -24.15%; over the trailing twelve months it is -28.86%. Its 52-week range spans $81.97 to $141.23. Analyst consensus is strong buy with an average price target of $117.75. Rallies surfaces ABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Abbott Labs Earns Outperform Rating, Eyes Diagnostics, Nutrition and Multi-Cancer Tests: Baird has initiated coverage of Abbott Laboratories with an Outperform rating, forecasting growth driven by its diversified medical device, diagnostics and nutrition product pipeline. Recent analysis highlights the potential commercialization of multi-cancer blood screening tests and compares Abbott’s offerings to Intuitive Surgical’s robotics franchise.
| Metric | Value |
|---|---|
| Price | $95.40 |
| Market Cap | $166.17B |
| P/E Ratio | 26.57 |
| EPS | $3.59 |
| Dividend Yield | 0.63% |
| 52-Week High | $141.23 |
| 52-Week Low | $81.97 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $45.13B |
| Net Income | $6.28B |
| Gross Margin | 56.26% |
20 analysts cover ABT: 0 strong buy, 16 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $117.75.